Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Old drug, new hope? ivermectin tested for stubborn skin disease

NCT ID NCT06251739

Disease control Sponsor: International Centre for Diarrhoeal Disease Research, Bangladesh Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early study tested whether the common anti-parasite drug ivermectin could treat post-kala-azar dermal leishmaniasis (PKDL), a skin condition that can spread a serious disease. Thirty people in Bangladesh received either ivermectin pills for 3 months or the standard drug miltefosine for 12 weeks. Researchers checked if ivermectin cleared the parasite and reduced skin lesions safely. The goal is to find a shorter, safer treatment to help eliminate PKDL.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Ivermectin (oral tablet)
What this could lead to
If ivermectin works, it could offer a shorter, safer, and cheaper treatment for PKDL, helping eliminate the disease in affected regions.
What could go wrong
This is a very early, small (30 people) proof-of-concept trial. Results may not hold up in larger studies, and ivermectin's effectiveness against PKDL is unproven in humans.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Early phase 1

The earliest testing in people: a first look at safety, in a very small group.

Participants

30 people

The number who actually took part.

Started

Oct 2023

Finished

Jan 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Confirmed PKDL cases of either sex * Clinically healthy except for skin lesions * Voluntary participation through informed, voluntary written consent Exclusion Criteria: * Incompliance with any inclusion criteria * Pregnant/lactating women

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Post kala-azar dermal leishmaniasis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

visceral leishmaniasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Post kala-azar dermal leishmaniasis

Contacts and locations

Locations

  • International Centre for Diarrhoeal Disease Research, Bangladesh

    Dhaka, Dhaka Division, 1212, Bangladesh

More trials for these conditions

Other studies related to the condition(s) this trial covers.